The Food and Drug Administration placed a partial hold on the clinical studies being conducted by CTI BioPharma Corp. Nasdaq: CTIC) for pacritinib. The stock price plunged 60 cents to close at $0.44.
FDA places partial hold on CTI BioPharma studies
February 08, 2016 at 18:14 PM EST